ENGAGE-501: Phase II study of entinostat (SNDX-275) in relapsed and refractory hodgkin lymphoma

Haematologica

Volumn 101, Issue 8, 2016, Pages 968-975

  Batlevi, Connie Lee ^a   Kasamon, Yvette ^b   Bociek, R Gregory ^c   Lee, Peter ^d   Gore, Lia ^e   Copeland, Amanda ^a   Sorensen, Rachel ^f   Ordentlich, Peter ^f   Cruickshank, Scott ^f   Kunkel, Lori ^f   Buglio, Daniela ^g   Hernandez Ilizaliturri, Francisco ^h   Younes, Anas ^a,g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Tower Cancer Research Foundation ^*  (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f Syndax Pharmaceuticals   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; ENTINOSTAT; THYMUS AND ACTIVATION REGULATED CHEMOKINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYTOKINE; HISTONE DEACETYLASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERICARDITIS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TUMOR GROWTH; BLOOD; CLINICAL TRIAL; DRUG RESISTANCE; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODAL IMAGING; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; COMBINED MODALITY THERAPY; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PYRIDINES; RECURRENCE; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84980417467     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.142406     Document Type: Article

References (25)

1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386-2395.
2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065-2071.
3. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-2533.
4. Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013), Study. KEYNOTE-013; ASH Meeting. 2014.
5. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311-319.
6. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
7. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015; 125(8):1236-1243.
8. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.
9. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008;112(4):1424-1433.
10. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood. 2011;117(10):2910-2917.
11. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8(3):239-245.
12. Kim K, Skora AD, Li Z, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA. 2014;111(32):11774-11779.
13. Oki Y, Buglio D, Zhang J, et al. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and Tcell PD1 expression. Blood Cancer J. 2014;4:e236.
14. Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 2012; 53(2):259-262.
15. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197-2203.
16. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011; 12(13):1222-1228.
17. Suzuki T, Ando T, Tsuchiya K, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem. 1999;42(15):3001-3003.
18. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 1999;96(8):4592-4597.
19. Gore L, Rothenberg ML, O’Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008; 14(14):4517-4525.
20. Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol. 2011; 39(10):1007-1017.e1.
21. Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs. 2011;20(10):1455-1467.
22. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
23. Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R, Baker SD. A liquid chromatography/ tandem mass spectrometry assay to quantitate MS-275 in human plasma. J Pharm Biomed Anal. 2007;43(2):784-787.
24. Morschhauser F, Terriou L, Coiffier B, et al. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015;33(2):423-431.
25. Shen L, Ciesielski M, Ramakrishnan S, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 2012; 7(1):e30815.